Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk management advisory committee plays it safe

Executive Summary

FDA postpones Drug Safety & Risk Management Advisory Committee Sept. 18 and 19 meeting as a result of Hurricane Isabel. Committee was slated to discuss labeling and packaging of drug products in low-density polyethylene plastic vials Sept. 18 and screening methods for look-alike, sound-alike proprietary drug names Sept. 19 (1"The Pink Sheet" June 29, 2003, In Brief)...

You may also be interested in...

Sound-alike, look-alike drug names

FDA Drug Safety & Risk Assessment Advisory Committee will discuss current screening methods for sound-alike and look-alike proprietary drug names Sept. 19. The meeting will take place at the Holiday Inn in Silver Spring, Md. at 8 a.m. [Editor's note: To sign up for a webcast or video of this meeting, go to]...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts